$MIRM
Mirum Pharmaceuticals, Inc.

2019 Q2 Form 10-Q Financial Statement

#000156459019033345 Filed on August 28, 2019

View on sec.gov

Income Statement

Concept 2019 Q2 2018 Q2
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.450M
YoY Change
% of Gross Profit
Research & Development $11.59M
YoY Change
% of Gross Profit
Depreciation & Amortization $40.00K
YoY Change
% of Gross Profit
Operating Expenses $14.03M
YoY Change
Operating Profit -$14.03M
YoY Change
Interest Expense $480.0K
YoY Change
% of Operating Profit
Other Income/Expense, Net $9.000K
YoY Change
Pretax Income -$13.56M
YoY Change
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$13.56M -$10.00K
YoY Change 135470.0%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$589.1K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q2 2018 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $84.19M
YoY Change
Cash & Equivalents $41.82M $0.00
Short-Term Investments $42.38M
Other Short-Term Assets $700.0K
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $84.90M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment $1.400M
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $16.10M
YoY Change
Other Assets $1.900M
YoY Change
Total Long-Term Assets $19.40M
YoY Change
TOTAL ASSETS
Total Short-Term Assets $84.90M
Total Long-Term Assets $19.40M
Total Assets $104.3M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.300M
YoY Change
Accrued Expenses $8.800M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $11.10M
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $1.300M
YoY Change
Total Long-Term Liabilities $1.300M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $11.10M
Total Long-Term Liabilities $1.300M
Total Liabilities $12.40M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$36.86M
YoY Change
Common Stock $1.894M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$34.94M $0.00
YoY Change
Total Liabilities & Shareholders Equity $104.3M
YoY Change

Cashflow Statement

Concept 2019 Q2 2018 Q2
OPERATING ACTIVITIES
Net Income -$13.56M -$10.00K
YoY Change 135470.0%
Depreciation, Depletion And Amortization $40.00K
YoY Change
Cash From Operating Activities -$8.010M
YoY Change
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$58.40M
YoY Change
Cash From Investing Activities -$58.41M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 58.76M
YoY Change
NET CHANGE
Cash From Operating Activities -8.010M
Cash From Investing Activities -58.41M
Cash From Financing Activities 58.76M
Net Change In Cash -7.660M
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$8.010M
Capital Expenditures $0.00
Free Cash Flow -$8.010M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q2 us-gaap Common Stock Value
CommonStockValue
1000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2019Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1893000
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
34000
CY2019Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-36862000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-17348000
CY2019Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
28000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
-34940000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-17313000
CY2019Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
104266000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
51975000
CY2019Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
180000000
CY2019Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1161718
CY2019Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
705273
CY2019Q2 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
456445
CY2018Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
550781
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11589000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16452000
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2445000
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
14034000
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-14034000
CY2019Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
468000
CY2019Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
9000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-13557000
us-gaap Net Income Loss
NetIncomeLoss
-19514000
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.31
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-7.70
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2551822
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2534877
CY2019Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
46000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
46000
CY2019Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-18000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-18000
CY2019Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13529000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19486000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
218000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-10146000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-5957000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
-23052000
us-gaap Profit Loss
ProfitLoss
-19514000
us-gaap Share Based Compensation
ShareBasedCompensation
1859000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
51963000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
43000
mirm Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
72000
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
41817000
mirm Amortization Of Premium On Investments
AmortizationOfPremiumOnInvestments
-35000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
654000
mirm Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
33000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
89000
mirm Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities
7865000
mirm Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
43000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10443000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
58401000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
44000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-58445000
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
59977000
us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
1217000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
58760000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-18000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1418000
us-gaap Payments For Tenant Improvements
PaymentsForTenantImprovements
461000
mirm Deferred Initial Public Offering Costs In Accounts Payable And Accrued Expenses
DeferredInitialPublicOfferingCostsInAccountsPayableAndAccruedExpenses
565000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of condensed consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the financial statements and accompanying notes. The most significant estimates in the Company&#8217;s condensed consolidated financial statements relate to accrued research and development expenses, the valuation of common stock, equity awards and the valuation allowance of deferred tax assets resulting from net operating losses. These estimates and assumptions are based upon historical experience, knowledge of current events and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results could differ materially from those estimates. </p>
CY2019Q2 mirm Accrued Clinical Trials Current
AccruedClinicalTrialsCurrent
1513000
CY2019Q2 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2019Q2 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
0
CY2019Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
43000
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
0
CY2019Q2 mirm Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis
CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
90088000
CY2019Q2 mirm Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
49000
CY2019Q2 mirm Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
3000
CY2019Q2 mirm Cash Equivalents And Available For Sale Securities Debt Securities
CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities
90134000
CY2019Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
31651000
CY2019Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
42375000
CY2019Q2 mirm Cash Cash Equivalents And Short And Long Term Investments
CashCashEquivalentsAndShortAndLongTermInvestments
100300000
CY2018Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10000
mirm Investments Classified As Cash And Cash Equivalent Original Maturities
InvestmentsClassifiedAsCashAndCashEquivalentOriginalMaturities
P3M
CY2019Q2 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2019Q2 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2019Q2 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
16108000
mirm Available For Sale Securities Maximum Remaining Contractual Maturity Period
AvailableForSaleSecuritiesMaximumRemainingContractualMaturityPeriod
P2Y
us-gaap Available For Sale Securities Gross Realized Losses
AvailableForSaleSecuritiesGrossRealizedLosses
0
us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
0
CY2019Q2 mirm Accrued Milestones Current
AccruedMilestonesCurrent
3000000
CY2019Q2 mirm Accrued Costs Current
AccruedCostsCurrent
1542000
CY2018Q4 mirm Accrued Costs Current
AccruedCostsCurrent
1310000
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2018-05-02
CY2018Q4 mirm Accrued Clinical Trials Current
AccruedClinicalTrialsCurrent
785000
CY2019Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
922000
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
70000
CY2019Q2 mirm Accrued Contract Manufacturing And Non Clinical Costs Current
AccruedContractManufacturingAndNonClinicalCostsCurrent
803000
CY2019Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
759000
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
15000
CY2019Q2 us-gaap Proceeds From Issuance Of Redeemable Convertible Preferred Stock
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
60000000
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
18148373
CY2018Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
9347681
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1641000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1859000
CY2019Q1 us-gaap Area Of Land
AreaOfLand
5600
CY2019Q1 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P4Y
CY2019Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
The lease term is for approximately four years with the option to extend the term for one five-year term.
us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2019Q2 us-gaap Tenant Improvements
TenantImprovements
400000
CY2019Q2 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.08
CY2019Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
116000
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
436000
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
448000
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
460000
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
252000
CY2019Q2 mirm Lessee Operating Lease Liability Payments Due Year Six
LesseeOperatingLeaseLiabilityPaymentsDueYearSix
15000
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1727000
CY2019Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
266000
CY2019Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1461000
CY2019Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
0
us-gaap Operating Lease Payments
OperatingLeasePayments
0
CY2019Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
100000
us-gaap Operating Lease Expense
OperatingLeaseExpense
100000
CY2018Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
0
CY2019Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2018Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0

Files In Submission

Name View Source Status
0001564590-19-033345-index-headers.html Edgar Link pending
0001564590-19-033345-index.html Edgar Link pending
0001564590-19-033345.txt Edgar Link pending
0001564590-19-033345-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
mirm-10q_20190630.htm Edgar Link pending
mirm-20190630.xml Edgar Link completed
mirm-20190630.xsd Edgar Link pending
mirm-20190630_cal.xml Edgar Link unprocessable
mirm-20190630_def.xml Edgar Link unprocessable
mirm-20190630_lab.xml Edgar Link unprocessable
mirm-20190630_pre.xml Edgar Link unprocessable
mirm-ex311_8.htm Edgar Link pending
mirm-ex312_9.htm Edgar Link pending
mirm-ex321_7.htm Edgar Link pending
mirm-ex322_6.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending